Document is current

Article History

First Online: 6 June 2025

Competing interests

: No funders were involved in the preparation of this piece. The content is solely the responsibility of the authors and does not necessarily represent the official views of their institutions. R.Y. has acted as an advisor for Amgen, Erasca, Loxo@Lilly, Merck, Mirati Therapeutics and Revolution Medicines; has received honoraria as a speaker from Zai Lab; and has received research support to her institution from Boehringer Ingelheim, Boundless Bio, Daiichi Sankyo, Mirati Therapeutics, Parabilis, Pfizer and Revolution Medicines. D.J.S. has received honoraria as a consultant or advisor from Abbvie, AstraZeneca and Merck; has 3% ownership in US Patent no. 9.675.663 (a test to predict response to TUSC2/FUS1 gene therapy); receives book royalties; and works in an institution that receives research support from a broad range of pharmaceutical companies. V.S. receives research funding for clinical trials through his institution from Abbvie, Agensys, Alfasigma, Altum, Amgen, Bayer, BERG Health, Blueprint Medicine, Boston Biomedical, Boston Pharmaceuticals, D3 Bio, Dragonfly Therapeutics, Exelixis, Fujifilm, GlaxoSmithKline, Idera Pharmaceuticals, Incyte, Inhibrix, Loxo@Lilly, MedImmune, NanoCarrier, Novartis, PharmaMar, Pfizer, Relay Therapeutics, Roche–Genentech, Takeda, Turning Point Therapeutics, and Vegenics; has had paid consulting and/or advisory roles paid to his institution from Abbvie, Astex Pharmaceuticals, AstraZeneca, Bayer, Endeavor Biomedicines, Genmab, Incyte, LabGenius therapeutics, Loxo@Lilly, Novartis, Obsidian Therapeutics, Pfizer, Pheon Therapeutics, Regeneron, Relay Therapeutics, Revolution Medicines and Roche/Genentech; and has had other consulting, advisory and/or continuing medical education-related roles for Bayer, Clinical Care Communications, Daiichi Sankyo, Helsinn Healthcare, Illumina, Incyte, Jazz Pharmaceuticals, Loxo@Lilly, Med Learning Group, Medscape, Novartis, OncLive, PERS and Relay Therapeutics. F.S.D. owns the consulting firm Pharmagellan and receives advisory fees from its biopharmaceutical clients. M.V. declares no competing interests.